

PRESS RELEASE

Guerbet reveals new ambitions for medical imaging

The new unit at Aulnay-sous-Bois, inaugurated today, enables the Group, specialized in contrast agents for medical imaging, to double its pharmaceutical production capacities in France in support of its international growth objectives.

Aulnay-sous-Bois, 3 July 2012

Guerbet (GBT), the contrast agent specialist for medical imaging, today inaugurates a new pharmaceutical filling and packaging unit on its principal production site at Aulnay-sous-Bois (Seine-Saint-Denis). The Group, which exports 72% of its production, thus enters a new key stage in its strategy of adapting its industrial infrastructure with a view to strengthening its leading positions in medical imaging.

This inauguration marks the completion of an ambitious modernization and specialization program for its four French industrial sites*, initiated in 2005, to increase its production capacities and enhance its competitiveness, and which represents an investment of € 197 million between 2005 and 2012. At Aulnay, 52 net jobs have been created since 2005 and € 74 million invested. The new pharmaceutical filling and packaging unit inaugurated today represents an investment of € 42 million between 2010 and 2012.

With an annual capacity of 20 million sterile vials and six million sterile softbags, this new unit, covering almost 10,000 m², enables Guerbet to double its pharmaceutical production capacities in France. Meeting the most demanding international standards, it will enable it to export all its pharmaceutical products to over 70 countries, including the United States, where Guerbet is preparing to launch its leading product, Dotarem.

This achievement also highlights the Group's determination to ensure the longevity of its infrastructure and its industrial jobs in France (70% of its pharmaceutical products are manufactured in France). It also consolidates its historical base in the Greater Paris Region, particularly in the Seine-Saint-Denis department, where Guerbet employs 580 people out of a total workforce of 1,000 in France.

The Aulnay site has 325 staff working in pharmaceutical production and in R&D.

As Yves L'Epine, CEO of the Guerbet Group explains *"The investments made at Aulnay-sous-Bois give Guerbet a new dimension by reinforcing its export capacities to the global market. We have upgraded our French facilities so that they meet international manufacturing requirements, thereby bolstering our development objectives.*

The success of this huge industrial program consolidates our mission, which consists of supplying contrast agents indispensable to diagnostic imaging to improve prognosis and quality of life for patients".

* located at Aulnay-sous-Bois (Seine-Saint-Denis), Gonesse (Val d'Oise), Lanester (Morbihan) and Marans (Charente Maritime). The Gonesse site is dedicated to the distribution of contrast agents and medical devices worldwide. The Lanester site is dedicated to chemicals production for X-ray contrast agents and the Marans site to fine chemicals for Dotarem (an MRI contrast agent) and Lipiodol (an X-ray contrast agent).

About Guerbet

Guerbet is the only pharmaceutical group dedicated to medical imaging on the world market. It has a comprehensive range of X-ray and MRI contrast agents to enhance diagnosis and overall patient care.

To discover new products and ensure its future development, Guerbet devotes significant resources to R&D every year: 210 staff and a sum equivalent to 11% of its sales.

Guerbet has a very strong presence in Europe with a market share of 25% and is developing its presence in the United States, South America and Asia.

Guerbet (GBT), listed on the Euronext Paris Eurolist (compartment B), posted sales of € 378 million in 2011 with a 1,400-strong workforce, 1,000 of which work in France.

Guerbet is a member of the G5 Health association.

For more information on Guerbet, please go to www.guerbet.com.

Press contacts:

Guerbet

Anne-Laure Delasalle, Communications Director

Tel: + 33 (0)1 45 91 50 03

anne-laure.delasalle@guerbet-group.com

Agence Presse-Papiers:

Tel: + 33 (0) 1 46 99 69 69

Danielle Maloubier: dm@pressepapiers.fr

Juliette Dumoulin: juliette.dumoulin@pressepapiers.fr

Guillaume de Chamisso: guillaume.dechamisso@pressepapiers.fr